This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABT-894

AbbVie Inc.

Drug Names(s): ABT-894, sofinicline

Description: ABT-894 is a neuronal nicotinic acetylcholine receptor (NNR) modulator targeting the alpha4beta2 NNR receptor. In preclinical models, ABT-894 demonstrated a pain-relieving effect in line with that of morphine but without the adverse effects normally associated with morphine and other similar drugs.

Deal Structure: ABT-894 was selected as the first development candidate under a research, development and license agreement with NeuroSearch A/S covering Neuronal Nicotinic Receptor (NNR) modulators. Abbott is responsible for the clinical development and commercialisation of ABT-894 and will under the terms of the agreement finance all development costs and pay milestones and royalties to NeuroSearch.

Partners: NeuroSearch A/S


ABT-894 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug